Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Prostatic NeoplasmsFatigue
Interventions
DRUG

Methylphenidate Hydrochloride

Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.

DRUG

Matched Placebo

Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.

Trial Locations (1)

M5G 2M9

UHN Princess Margaret Hospital, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University Health Network, Toronto

OTHER